Table 2 Association between participant characteristics and second-booster uptakea

From: Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years

Characteristics

Adjusted HR (95% CI)

Age group (years)

 

60–69

Reference

70–79

1.49 (1.48–1.50)

≥80

1.57 (1.56–1.59)

Sex

 

Female

Reference

Male

1.13 (1.12–1.14)

Population sector

 

General Jewish

Reference

Ultra-Orthodox Jewish

0.81 (0.79–0.83)

Arab

0.59 (0.57–0.60)

SES

1.18 (1.18–1.18)b

Clinical risk factors

 

Asthma

1.04 (1.03–1.06)

Chronic heart failure

0.94 (0.92–0.95)

Chronic kidney failure

1.04 (1.02–1.05)

COPD

0.97 (0.96–0.99)

Diabetes

1.02 (1.01–1.03)

Hypertension

1.11 (1.10–1.12)

Ischemic heart disease

1.05 (1.04–1.06)

Obesity

1.03 (1.03–1.04)

Lung cancer

1.08 (1.04–1.12)

History of stroke

0.93 (0.92–0.94)

History of TIA

1.02 (1.01–1.04)

Current or former smoking

0.99 (0.98–1.00)

  1. aThe association between all covariates and second-booster uptake was estimated using a multivariate Cox proportional hazards regression model. The higher the HR, the greater the association between the listed characteristic and vaccine uptake.
  2. bThe HR for SES and second-booster uptake was 1.179 (95% CI: 1.176–1.181).
  3. COPD, chronic obstructive pulmonary disease; SES, socioeconomic status; TIA, transient ischemic attack.
Back to article page